BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response 105

Immune Response Vaccination Vaccine Trials 105

Scienmag

NOVEMBER 16, 2021

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84

Protein Vaccination Vaccine Immune Response 84

Pharmaceutical Technology

OCTOBER 25, 2022

A human monoclonal antibody, Imfinzi attaches to the PD-L1 protein and hinders the PD-L1 interaction with the PD-1 and CD80 proteins. Imjudo is also a human monoclonal antibody and hinders cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity.

Protein 173

Protein Immune Response Antibody FDA Approval 173

Scienmag

NOVEMBER 10, 2020

Mid-range level of immune protein associated with lowest risk Philadelphia, November 10, 2020 – The causes of autism spectrum disorder (ASD) – including genetic and environmental factors – are not entirely understood.

Immune Response 70

Immune Response Genetics Protein Medicine 70

Scienmag

MAY 26, 2021

A […].

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

Medical Xpress

FEBRUARY 21, 2023

PCB2DG, a polyphenol with anti-inflammatory properties, works by targeting and directly interacting with the major glutamine transporter protein, alanine serine cysteine transporter 2 (ASCT2), to inhibit the uptake of glutamine, an important amino acid found in the blood.

Immune Response 71

Immune Response Regulation Protein 71

XTalks

FEBRUARY 5, 2025

Avtozma is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist that works by targeting specific inflammatory proteins to dampen immune responses. Avtozma was submitted for regulatory approval to the FDA in January 2024 and the European Medicines Agency (EMA) in February 2024.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

Pharmaceutical Technology

FEBRUARY 15, 2023

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Antibody 261

Antibody Immune Response Protein Development 261

Medical Xpress

MAY 10, 2023

SLFN 12 shuts down viral protein production and helps virus-infected cells to escape from anti-HIV therapy and immune responses. These findings pave the way for improving therapeutic strategies that aim to cure HIV infections.

Immune Response 109

Immune Response Protein Production Research 109

Scienmag

OCTOBER 14, 2020

Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction, supports a mechanism critical for survival in mouse models of sepsis and colitis Credit: UC San Diego Health Sciences The immune response to infections is a delicate balance.

Protein 67

Protein Immune Response Bacteria Allergies 67

Pharmaceutical Technology

MAY 29, 2023

A protein-based vaccine, Nuvaxovid has been recommended for MA for use as a primary series in individuals of the age 12 years and above and as a booster in those aged 18 years and older to prevent Covid-19. NVX-CoV2373 is developed by making copies of the surface spike protein of the SARS-CoV-2 virus that causes Covid.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

BioPharma Reporter

MAY 25, 2021

An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that inefficiency. Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC).

Vaccination 91

Vaccination Vaccine Immune Response Production 91

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 86

Immune Response Vaccination Vaccine Protein 86

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Medical Xpress

FEBRUARY 14, 2023

This limits glucose availability for immune cells and therefore dampens the body's anti-cancer immune response. Tumor cells typically alter their energy metabolism and increase glucose uptake to support their rapid division and spread.

Immune Response 72

Immune Response Protein Scientist 72

Medical Xpress

APRIL 17, 2023

The findings, published in Science Translational Medicine, suggests that breaches in damaged gums allow bacteria in the mouth to seep into the bloodstream, activating an immune response that ultimately pivots to target the body's own proteins and causes arthritis flareups.

Immune Response 98

Immune Response Bacteria Protein Medicine 98

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. This is an important leap forward to better understand individualised protein-protein interactions on cancer cells, moving us toward delivering on the promise of personalised medicine.”

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. Novavax president and CEO Stanley Erck said: “Canadians now have access to our protein-based Nuvaxovid Covid-19 vaccine as an adult booster.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Medical Xpress

FEBRUARY 28, 2025

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the cancer.

Genome 87

Genome Genomics Immune Response DNA 87

pharmaphorum

JANUARY 12, 2021

For instance, oral vaccines could allow repeat dosing without a treatment-limiting anti-vector response – where the body generates an immune response against the harmless, non-replicating viruses used to deliver the COVID-19 antigens. There are other theoretical advantages as well.

Licensing 119

Licensing Licensing Vaccination Vaccine 119

XTalks

OCTOBER 24, 2024

In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis. While research is still ongoing, studies suggest that low-calorie diets, the Mediterranean diet and protein restriction may reduce inflammation.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

BioTech 365

AUGUST 19, 2021

Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong … Continue reading →

Immune Response 40

Immune Response Protein Vaccination Vaccine 40

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Medical Xpress

DECEMBER 16, 2022

They have just discovered that a key immune alarm protein previously believed to calm down the immune response actually does the opposite. Scientists from Trinity College Dublin have made an important breakthrough in understanding how inflammation is regulated.

Immune Response 80

Immune Response Protein Scientist Regulation 80

Scienmag

DECEMBER 9, 2021

When the body attempts to fight off an infection, immune cells called neutrophils may shoot out spider web-like networks of toxic proteins to help contain the invaders.

Immune Response 60

Immune Response Containment Protein Regulation 60

Scienmag

NOVEMBER 16, 2020

Cincinnati Children’s team reports controlling the BCAP protein could slow overactive immune response in IBD, rheumatoid arthritis or accelerate response against tumors Credit: Cincinnati Children’s Managing the activity of the BCAP protein could help the body repair intestinal tissue from damage caused by inflammation, according to a new (..)

Immune Response 78

Immune Response Protein Allergies Medicine 78

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

pharmaphorum

DECEMBER 4, 2020

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine. VLA15 has demonstrated a promising immune response and safety data in pre-clinical and clinical studies so far.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Scienmag

OCTOBER 6, 2020

— Researchers at Penn State College of Medicine now better understand the role of a protein, interleukin-21 (IL-21), in the immune system response to infections in the nervous system. HERSHEY, Pa.

Immune Response 40

Immune Response Protein Medicine Research 40

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

Pharmaceutical Technology

MAY 17, 2023

It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body. The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion CEO Per Norlén said: “We believe that ExpreS 2 ion´s superb platforms for the production of complex proteins are a great match with our AI platform for target discovery and our novel technologies for inducing strong immune responses.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

FEBRUARY 15, 2023

The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins. The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

XTalks

OCTOBER 12, 2021

The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. as a potential trigger for rheumatoid arthritis. With the finding that 14-3-3?

Vaccination 105

Vaccination Vaccine Research Immune Response 105